{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:10:49Z","timestamp":1791245449555,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.03.025","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T23:25:33Z","timestamp":1620689133000},"page":"346-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Real-life experience with ceftolozane\/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry"],"prefix":"10.1016","volume":"25","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Zvonar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Savoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.03.025_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2021.03.025_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkz283","article-title":"42936 pathogens from Canadian hospitals: 10 years of results (2007\u201316) from the CANWARD surveillance study","volume":"74","author":"Zhanel","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.025_bib0003","doi-asserted-by":"crossref","first-page":"e00830","DOI":"10.1016\/j.idcr.2020.e00830","article-title":"Ceftolozane\/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa","volume":"21","author":"Romano","year":"2020","journal-title":"IDCases"},{"key":"10.1016\/j.jgar.2021.03.025_bib0004","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s15010-020-01390-y","article-title":"Efficacy and safety of ceftolozane\/tazobactam as a therapeutic option for complicated skin and soft tissue infections by MDR\/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single center experience","volume":"48","author":"Buonomo","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.03.025_bib0005","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam for the treatment of extensively drug resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature","author":"Meschiari","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.03.025_bib0006","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/antibiotics9100640","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for multidrug-resistant Gram-negative infections in immunocompetent patients: a single-center retrospective study","volume":"9","author":"Cultera","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2021.03.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106158","article-title":"Use of continuous-infusion ceftolozane\/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature","volume":"56","author":"Sheffield","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.03.025_bib0008","doi-asserted-by":"crossref","first-page":"ofaa409","DOI":"10.1093\/ofid\/ofaa409","article-title":"Outpatient parenteral antimicrobial therapy with ceftolozane\/tazobactam via continuous infusion for multidrug-resistant Pseudomonas aeruginosa osteomyelitis","volume":"7","author":"Otero","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.025_bib0009","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s15010-020-01510-8","article-title":"Continuous infusion of ceftolozane\u2013tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis","volume":"49","author":"Winans","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.03.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1178633720905977","article-title":"Experience with ceftolozane\u2013tazobactam for the treatment of serious Pseudomonas aeruginosa infections in Saudi tertiary care center","volume":"13","author":"Bosaeed","year":"2020","journal-title":"Infect Dis (Auckl)"},{"key":"10.1016\/j.jgar.2021.03.025_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02291-19","article-title":"Real-world experience with ceftolozane\u2013tazobactam for multidrug-resistant Gram-negative bacterial infections","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.025_bib0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkx468","article-title":"In vitro activity of ceftolozane\/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study 2008\u201316","volume":"73","author":"Walkty","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.03.025_bib0013","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jgar.2021.03.025_bib0014","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical efficacy of ceftolozane\u2013tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.025_bib0015","doi-asserted-by":"crossref","first-page":"e02340","DOI":"10.1128\/AAC.02340-18","article-title":"A case\u2013control study of real-life experience with ceftolozane\u2013tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.025_bib0016","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicenter nationwide clinical experience","volume":"7153","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.03.025_bib0017","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"31","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.025_bib0018","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ajhp\/zxz011","article-title":"Use of continuous infusion ceftolozane\/tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis","volume":"76","author":"Davis","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2021.03.025_bib0019","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","article-title":"Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of targeted attainment in patients infected with Pseudomonas aeruginosa","volume":"38","author":"Pilmis","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.025_bib0020","doi-asserted-by":"crossref","first-page":"ofz416","DOI":"10.1093\/ofid\/ofz416","article-title":"Higher MICs (>2 mg\/L) predict 30-day mortality in patients with lower respiratory tract infections caused by multidrug and extensively drug-resistant Pseudomonas aeruginosa treated with ceftolozane\/tazobactam","volume":"6","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:57:43Z","timestamp":1761991063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":20,"alternative-id":["S2213716521000953"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.03.025","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life experience with ceftolozane\/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}